How Funders Price a Claim: A Worked Example of Multiples, IRR and the Waterfall
One USD 2 million funding deal, three pricing structures, three outcomes. This worked example shows how much of the recovery the claimant keeps, and which term-sheet clauses cost the most.
Why the Headline Price Hides the Real Cost of Litigation Funding
A funder's term sheet leads with a number: "3x", "25%" or "30% IRR". It doesn't tell you what you'll keep. The real cost of litigation funding depends on three things that only show up when you model the deal: how much capital the funder actually deploys, how long the case runs, and where the funder sits in the order of payment when money comes in.
So the useful question isn't "which funder is cheapest?" It's "which pricing structure leaves us the most money in the outcomes we think are likely?" A structure that looks generous on an early settlement can take most of the recovery after an appeal. The reverse is also true.
Below, we run one hypothetical commercial claim through three common pricing models and three outcomes. Every figure is illustrative. Pricing, permitted structures and tax treatment differ by jurisdiction and by deal, so check any real term sheet with litigation counsel and a funding broker or independent adviser.
The Hypothetical Claim and Its Assumptions
Hypothetical worked example. Say a mid-sized manufacturer has a breach-of-contract and misrepresentation claim against a former distribution partner, pleaded at roughly USD 15 million. Its lawyers budget USD 2 million through trial. A funder commits that USD 2 million to cover legal fees, experts and disbursements, and draws it down in stages.
- Funding commitment: USD 2.0 million, with returns calculated on capital actually deployed (more on why this matters below).
- Adverse costs cover: an after-the-event (ATE) policy with USD 1 million of cover, premium deferred and payable only from a successful recovery.
- Outcome 1, early settlement: settles at month 12 for USD 8 million. Deployed capital: USD 0.6 million. ATE premium: USD 0.2 million.
- Outcome 2, trial win: judgment collected at month 30 for USD 12 million. Deployed capital: USD 1.6 million. ATE premium: USD 0.4 million.
- Outcome 3, appeal: the defendant appeals, the judgment is upheld and USD 12 million is collected at month 48. Deployed capital: the full USD 2.0 million. ATE premium: USD 0.5 million, including a top-up for appeal cover.
To keep the comparison clean, we leave out conditional fee uplifts, enforcement costs and tax.
Three Pricing Structures Applied to the Same Claim
Funders such as Burford Capital, Omni Bridgeway and Harbour, along with many smaller regional players, use variations of three basic models. Typical 2026 market ranges vary widely by contract, case risk and claim size, so confirm terms with each funder.
| Structure | How the funder's return is calculated | Typical 2026 market range |
|---|---|---|
| A: Multiple | 3x deployed capital (includes return of that capital) | 2x to 4x deployed |
| B: Percentage | Return of deployed capital plus 20% of gross recovery | 15% to 40% of proceeds |
| C: Time-ratcheted multiple | 2x deployed if resolved by month 18, 3x by month 36, 4x after | Steps of roughly 0.5x to 1x every 6 to 12 months |
Many real term sheets combine these into "greater of" formulas, for example the higher of 3x deployed or 25% of proceeds. If yours does, model each limb separately and take the higher figure for every outcome. The funder will.
Jurisdiction decides which models are available. In England and Wales, the 2023 PACCAR decision pushed many funders toward multiple-based pricing and away from a share of damages; check the current status of any legislative fix before relying on either approach. Rules on champerty, fee-sharing with lawyers and arbitration funding also vary across Singapore, Hong Kong, India, the EU, Australia and individual US states.
The Litigation Funding Waterfall: Who Gets Paid First
The litigation funding waterfall is set out in the funding agreement and often in a separate priorities deed signed by the claimant, funder and law firm. It fixes the order in which recovered money is paid out. A common order, though not a universal one:
- ATE insurer's deferred premium
- Funder's return of deployed capital
- Funder's profit share or multiple
- Law firm's deferred or conditional fees, if any
- Claimant receives the remainder
The claimant is paid last. In a strong win, that costs little. In a disappointing settlement, it can leave you with almost nothing.
After-the-event insurance cost is the line item most often overlooked. Deferred, contingent premiums are typically a meaningful fraction of the cover limit and frequently step up as the case nears trial. In loser-pays jurisdictions such as England and Wales, and in parts of Europe, ATE cover is often essential and funders may require it. In England and Wales the premium is generally not recoverable from the opponent; rules differ elsewhere. In the US, where each side usually bears its own costs, ATE matters much less. Availability and market practice vary, so ask a broker what is actually written in your forum.
What the Claimant Keeps in Each Outcome
Here is the same claim run through all three structures. All figures are in USD millions and hypothetical. "Net to claimant" means recovery minus the ATE premium and the funder's total take.
| Outcome | Recovery | A: 3x multiple | B: capital + 20% | C: ratchet |
|---|---|---|---|---|
| Early settlement (month 12) | 8.0 | Funder 1.8 / Claimant 6.0 (75%) | Funder 2.2 / Claimant 5.6 (70%) | Funder 1.2 / Claimant 6.6 (83%) |
| Trial win (month 30) | 12.0 | Funder 4.8 / Claimant 6.8 (57%) | Funder 4.0 / Claimant 7.6 (63%) | Funder 4.8 / Claimant 6.8 (57%) |
| Appeal (month 48) | 12.0 | Funder 6.0 / Claimant 5.5 (46%) | Funder 4.4 / Claimant 7.1 (59%) | Funder 8.0 / Claimant 3.5 (29%) |
Three points stand out. First, the ratchet is the cheapest option on an early settlement and the most expensive if the case drags on: after the appeal, the claimant keeps less than a third of a USD 12 million recovery. Second, the percentage model is the most stable across outcomes, because the funder's profit tracks the recovery rather than time or spend. Third, a straight multiple gets worse as more capital is drawn, so a budget overrun raises the funder's return directly.
If the counterparty is well-funded and likely to appeal, Structure B is the better fit here, even though its early-settlement cost is the highest of the three. If the defendant is under real pressure to settle, the ratchet is the better bet.
Litigation Funding Multiple vs IRR: Why Funders Quote Both
Funders price to a target internal rate of return, typically a hurdle well above ordinary credit returns and higher for riskier cases. They quote multiples because claimants find them easier to grasp. Comparing a litigation funding multiple vs IRR shows what time does to the funder's return.
The figures below are simplified annualized returns that treat all deployed capital as drawn on day one. Real IRRs run higher, because capital is drawn in stages and sits outstanding for less time:
- Structure A (3x): about 200% if settled at month 12, about 55% at month 30, about 32% at month 48.
- Structure B: about 267%, 44% and 22% respectively.
- Structure C: about 100%, 55% and 41% respectively.
A fixed multiple gives the funder a very high IRR on a quick settlement and a modest one on a long case. That's why funders add ratchets or IRR floors: they're protecting themselves against delay. A funder offering a fixed multiple is carrying duration risk. A funder offering a ratchet is passing it to you. Your own view of how long the case will last should decide which you accept.
Term-Sheet Red Flags and How to Choose a Structure
Check every term sheet for these clauses. Each can move the result more than a full turn of the headline multiple.
- Return calculated on committed rather than deployed capital. In our early-settlement case, 3x on the USD 2 million commitment would be USD 6 million, not USD 1.8 million. After the USD 0.2 million premium, the claimant would keep USD 1.8 million of a USD 8 million settlement.
- No floor on the claimant's share. Ask for a provision guaranteeing the claimant a minimum share of net proceeds, whichever formula applies.
- Commitment, arrangement or monitoring fees that count toward "deployed capital" and so earn the multiple themselves.
- Uncapped ratchet steps that keep rising during enforcement as well as during the merits phase.
- Settlement control. Clauses that let the funder block a reasonable settlement, or tie consent to its own return, should be narrowed. Better-drafted agreements send disputes to independent counsel.
- Termination terms. Check what the funder still recovers if it withdraws mid-case.
To choose a structure, build your own version of the table above using your lawyers' phased budget and at least three outcome scenarios, and weight each by its realistic probability. Get competing offers from at least three funders, ideally through a broker. Then pick the structure with the highest probability-weighted net figure for the claimant, not the lowest headline multiple, and have independent counsel review the priorities deed before you sign.
Frequently asked questions
What is a typical cost of litigation funding for a commercial claim?
Typical 2026 market ranges are roughly 2x to 4x deployed capital for multiple-based deals, or 15% to 40% of proceeds for percentage-based deals, often combined in a "greater of" formula. Pricing depends on case risk, duration, claim size and jurisdiction. Get several competing quotes and confirm terms directly with funders.
Is a multiple or a percentage better for the claimant?
It depends on how much the case is likely to recover and how long it will take. Multiples get more expensive as spend and time increase, but can look cheap on large, fast recoveries. Percentages are more predictable but cost more on early settlements. Model both against your own budget and outcome scenarios before choosing.
Do I need after-the-event insurance as well as funding?
In loser-pays jurisdictions such as England and Wales and parts of Europe, ATE cover against adverse costs is often essential, and funders frequently require it. The premium is usually deferred and contingent, paid from the recovery ahead of the funder. Where each side pays its own costs, as in most US cases, it is usually less relevant. Market availability varies, so ask a broker.
What happens if we lose the case?
Under non-recourse funding, the funder normally loses its investment and the claimant owes nothing back, while any ATE policy covers adverse costs up to its limit. Read the termination and breach clauses closely, because some agreements allow recovery from the claimant for misconduct or for settling without consent. A licensed litigation lawyer in your jurisdiction should review these terms.
Written by the Lexstack Cloud editorial team. Prices, features and rules change often - confirm details with the vendor or a licensed professional before you decide.